AbbVie Ventures
AbbVie's strategic venture arm investing in biotech, genomics, and therapeutic technology companies.
AbbVie Ventures is the corporate VC arm that actually gets it - they move fast for a pharma giant and their checks are meaningful. The team has real scientific chops and can open doors at AbbVie proper, which matters when you need partnership or acquisition conversations. That said, they're not leading rounds and their investment committee can get spooked by anything too far outside AbbVie's wheelhouse. If your biotech aligns with their therapeutic areas, they're gold. If not, don't waste time - they stick to their knitting religiously.
- —Best for: Biotech startups in immunology, oncology, or neuroscience needing pharma partnerships
- —Watch out for: Slow decision-making when deals fall outside core therapeutic areas
- —Known for: Scientific rigor and opening doors to AbbVie's massive commercial machine
AbbVie Ventures invests in early-stage biotech and pharmaceutical companies developing breakthrough therapies across multiple disease areas. They focus on companies that align with AbbVie's core therapeutic interests including immunology, oncology, and neuroscience.
Series A to Series C biotech and pharma companies, heavily weighted toward immunology, oncology, neuroscience, and rare diseases. Occasional digital health plays but primarily traditional drug development.
Former Genentech executive with deep immunology expertise. Known for her scientific rigor and ability to spot promising early-stage assets. Founders appreciate her hands-on approach to due diligence.
Former McKinsey consultant turned venture investor with strong operational background. Focuses on portfolio company value creation and has a reputation for being founder-friendly during tough fundraising cycles.
Have a specific question about AbbVie Ventures?
Ask Bernie →